Interleukin-35 and the tumor microenvironment

Interleukin-35 与肿瘤微环境

基本信息

项目摘要

PROJECT SUMMARY Inhibitory mechanisms within the tumor microenvironment represent major barriers to effective antitumor immunity. Although striking efficacy in a variety of tumor types has been reported in clinical trails with inhibitory receptor blockade, it's clear that additional inhibitory mechanisms will need to be targeted to substantially improve therapeutic outcome in most tumor types. Regulatory T cells (Tregs) are potent inhibitors of anti-tumor immunity. Although targeted Treg ablation results in rapid tumor shrinkage in multiple models of human cancer, this is not a viable therapeutic approach due to the subsequent severe autoimmune and inflammatory consequences. Thus more targeted approaches to limit Treg activity selectively in the tumor microenvironment are needed, along with in depth understanding of their mechanism of action. Although Tregs use multiple inhibitory mechanisms to control T cell function, it is unclear which are dominant in the tumor microenvironment and thus may be viable therapeutic targets in cancer. Interleukin-35 (IL35), an Ebi3/Il12a heterodimer, is an inhibitory cytokine produced by Tregs that is a potent suppressor of T cell proliferation and function. Treg-derived IL35 can also promote the development of an induced regulatory T cell population that suppresses via IL35 (iTr35), which in turn can contribute to the suppressive intratumoral milieu. However, the physiological impact and mechanism of action of IL35 within the tumor microenvironment are largely unknown. In this competitive renewal application, we will determine how IL35 modulates the tumor microenvironment. AIM 1: Dissecting the function and fate of IL35+ Tregs in the tumor microenvironment. Using Ebi3 reporter, conditional and linage tracing mice, we will determine the physiological importance of IL35 production by Tregs in tumors and the role and fate of Ebi3+ versus Ebi3– Tregs. AIM 2: Determining the impact of IL35 on CD8+ T cells within the tumor microenvironment. Using Ebi3 conditional mice, we will determine the impact of Treg-derived IL35 on the function and fate of CD8+ T cells in tumors. This project will have a significant impact of our understanding of the physiological importance and mechanism of action of IL35 in the tumor microenvironment. Given that we discovered IL35 and have many unique tools to probe its function, we are in the best position to conduct this research.
项目摘要 肿瘤微环境中的抑制机制是有效抗肿瘤的主要障碍。 免疫力尽管在临床试验中已经报道了在多种肿瘤类型中具有显著的功效,但是抑制性的抗肿瘤药物在临床试验中已经报道了在多种肿瘤类型中具有显著的功效。 受体阻滞剂,很明显,额外的抑制机制将需要有针对性的实质上 改善大多数肿瘤类型治疗效果。调节性T细胞(Regulatory T cells,TCFs)是一种有效的抗肿瘤抑制剂 免疫力尽管靶向Treg消融在多种人类癌症模型中导致肿瘤快速缩小, 这不是一种可行的治疗方法, 后果因此,更有针对性的方法可以选择性地限制肿瘤微环境中的Treg活性 沿着深入了解其作用机制。虽然Tencent使用多个 尽管存在控制T细胞功能的抑制机制,但尚不清楚哪些在肿瘤微环境中占主导地位 因此可能是癌症中可行的治疗靶点。白细胞介素-35(IL-35),一种Ebi 3/IL-112 α异源二聚体,是一种免疫调节剂。 T细胞增殖和功能的有效抑制因子。Treg衍生 IL 35还可以促进诱导的调节性T细胞群的发展,该调节性T细胞群通过IL 35抑制免疫应答。 (iTr35),这反过来可以有助于抑制性肿瘤内环境。然而,生理影响 IL 35在肿瘤微环境中的作用机制在很大程度上是未知的。在这个竞争激烈的 更新申请,我们将确定IL 35如何调节肿瘤微环境。 目的1:探讨IL 35 + T细胞在肿瘤微环境中的作用和转归。使用Ebi3报告器, 条件和谱系追踪小鼠,我们将确定TCFs产生IL 35的生理重要性, 在肿瘤中的作用以及Ebi3+与Ebi3-TcB的作用和命运。 目的2:确定IL 35对肿瘤微环境中的CD8 + T细胞的影响。使用Ebi3 在条件小鼠中,我们将确定Treg衍生的IL 35对CD8 + T细胞的功能和命运的影响。 肿瘤的 这个项目将对我们理解生理学的重要性产生重大影响, IL 35在肿瘤微环境中的作用机制。鉴于我们发现了IL35, 有许多独特的工具来探索它的功能,我们处于进行这项研究的最佳位置。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dario AA Vignali其他文献

The extent of metalloproteinase-mediated LAG3 cleavage limits the efficacy of PD1 blockade
  • DOI:
    10.1186/2051-1426-3-s2-p216
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Lawrence P Andrews;Andrea L Szymczak-Workman;Creg J Workman;Dario AA Vignali
  • 通讯作者:
    Dario AA Vignali
Remodulation of the tumor microenvironment by regulatory T cells
  • DOI:
    10.1186/2051-1426-3-s2-p409
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Chang Liu;Maria Chikina;Creg J Workman;Dario AA Vignali
  • 通讯作者:
    Dario AA Vignali
Elucidating the role of Neuropilin-1 in intra-tumoral regulatory T cell stability
  • DOI:
    10.1186/2051-1426-3-s2-p274
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Abigail E Overacre;Maria Chikina;Greg M Delgoffe;Dario AA Vignali
  • 通讯作者:
    Dario AA Vignali
Antigen presentation by tumor infiltrating B cells influences CD4 T cell phenotype and function in primary lung cancer patient tumors
  • DOI:
    10.1186/2051-1426-3-s2-p397
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Tullia Bruno;Peggy Ebner;Brandon Moore;Daniel Munson;John Mitchell;Jeffrey Kern;Dario AA Vignali;Jill Slansky
  • 通讯作者:
    Jill Slansky

Dario AA Vignali的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dario AA Vignali', 18)}}的其他基金

Regulatory T cells and the tumor microenvironment
调节性T细胞和肿瘤微环境
  • 批准号:
    10454307
  • 财政年份:
    2021
  • 资助金额:
    $ 38.03万
  • 项目类别:
Project 1: Evaluating the synergy of LAG3 and PD-1 in melanoma patients
项目1:评估LAG3和PD-1在黑色素瘤患者中的协同作用
  • 批准号:
    10683756
  • 财政年份:
    2021
  • 资助金额:
    $ 38.03万
  • 项目类别:
Project 1: Evaluating the synergy of LAG3 and PD-1 in melanoma patients
项目 1:评估 LAG3 和 PD-1 在黑色素瘤患者中的协同作用
  • 批准号:
    10469635
  • 财政年份:
    2021
  • 资助金额:
    $ 38.03万
  • 项目类别:
Regulatory T cells and the tumor microenvironment
调节性T细胞和肿瘤微环境
  • 批准号:
    10298246
  • 财政年份:
    2021
  • 资助金额:
    $ 38.03万
  • 项目类别:
Regulatory T cells and the tumor microenvironment
调节性T细胞和肿瘤微环境
  • 批准号:
    10670939
  • 财政年份:
    2021
  • 资助金额:
    $ 38.03万
  • 项目类别:
Project 1: Evaluating the synergy of LAG3 and PD-1 in melanoma patients
项目 1:评估 LAG3 和 PD-1 在黑色素瘤患者中的协同作用
  • 批准号:
    10270231
  • 财政年份:
    2021
  • 资助金额:
    $ 38.03万
  • 项目类别:
Project 2 - Modulation of Anti-Tumor Immunity by Inhibitory Receptors
项目2——抑制性受体调节抗肿瘤免疫
  • 批准号:
    10670296
  • 财政年份:
    2015
  • 资助金额:
    $ 38.03万
  • 项目类别:
Core A - Administrative Core
核心 A - 行政核心
  • 批准号:
    10239106
  • 财政年份:
    2015
  • 资助金额:
    $ 38.03万
  • 项目类别:
Core A - Administrative Core
核心 A - 行政核心
  • 批准号:
    10023664
  • 财政年份:
    2015
  • 资助金额:
    $ 38.03万
  • 项目类别:
Synergies among inhibitory receptors in tolerance, cancer & antiviral immunity
抑制性受体在耐受性、癌症方面的协同作用
  • 批准号:
    10470821
  • 财政年份:
    2015
  • 资助金额:
    $ 38.03万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了